Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer

Peter Schmid (Lead / Corresponding author), Sarah E. Pinder, Duncan Wheatley, Jane Macaskill, Charles Zammit, Jennifer Hu, Robert Price, Nigel Bundred, Sirwan Hadad, Alice Shia, Shah Jalal Sarker, Louise Lim, Patrycja Gazinska, Natalie Woodman, Darren Korbie, Matt Trau, Paul Mainwaring, Steven Gendreau, Mark R. Lackner, Mika DerynckTimothy R. Wilson, Hannah Butler, Gemma Earl, Peter Parker, Arnie Purushotham, Alastair Thompson

Research output: Contribution to journalArticle

36 Citations (Scopus)
110 Downloads (Pure)

Abstract

Purpose: Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy. Patients and Methods: In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to 2 weeks of preoperative treatment with anastrozole 1 mg once per day (n = 26) or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49). The primary end point was inhibition of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment. 

Results: There was significantly greater geometric mean Ki-67 suppression of 83.8% (one-sided 95% CI, ≥ 79.0%) for the combination and 66.0% (95% CI, ≤ 75.4%) for anastrozole (geometric mean ratio [combination: anastrozole], 0.48; 95% CI, ≤ 0.72; P = .004). PIK3CA mutations were not predictive of response to pictilisib, but there was significant interaction between response to treatment and molecular subtype (P =.03);for patients with luminal B tumors, the combination:anastrozole geometric mean ratio of Ki-67 suppression was 0.37 (95% CI, ≤ 0.67; P = .008), whereas no significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98). Multivariable analysis confirmed Ki-67 response to the combination treatment of patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression. Conclusion: Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.

Original languageEnglish
Pages (from-to)1987-1994
Number of pages8
JournalJournal of Clinical Oncology
Volume34
Issue number17
Early online date14 Mar 2016
DOIs
Publication statusPublished - 10 Jun 2016

Fingerprint

Phosphatidylinositol 3-Kinases
Estrogen Receptors
Breast Neoplasms
Neoplasms
Therapeutics
Cell Proliferation
Progesterone Receptors
anastrozole
Mutation
Population
Proteins

Cite this

Schmid, Peter ; Pinder, Sarah E. ; Wheatley, Duncan ; Macaskill, Jane ; Zammit, Charles ; Hu, Jennifer ; Price, Robert ; Bundred, Nigel ; Hadad, Sirwan ; Shia, Alice ; Sarker, Shah Jalal ; Lim, Louise ; Gazinska, Patrycja ; Woodman, Natalie ; Korbie, Darren ; Trau, Matt ; Mainwaring, Paul ; Gendreau, Steven ; Lackner, Mark R. ; Derynck, Mika ; Wilson, Timothy R. ; Butler, Hannah ; Earl, Gemma ; Parker, Peter ; Purushotham, Arnie ; Thompson, Alastair. / Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 17. pp. 1987-1994.
@article{232d59f7feeb4a33a3d15f3d31296378,
title = "Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer",
abstract = "Purpose: Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy. Patients and Methods: In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to 2 weeks of preoperative treatment with anastrozole 1 mg once per day (n = 26) or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49). The primary end point was inhibition of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment. Results: There was significantly greater geometric mean Ki-67 suppression of 83.8{\%} (one-sided 95{\%} CI, ≥ 79.0{\%}) for the combination and 66.0{\%} (95{\%} CI, ≤ 75.4{\%}) for anastrozole (geometric mean ratio [combination: anastrozole], 0.48; 95{\%} CI, ≤ 0.72; P = .004). PIK3CA mutations were not predictive of response to pictilisib, but there was significant interaction between response to treatment and molecular subtype (P =.03);for patients with luminal B tumors, the combination:anastrozole geometric mean ratio of Ki-67 suppression was 0.37 (95{\%} CI, ≤ 0.67; P = .008), whereas no significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98). Multivariable analysis confirmed Ki-67 response to the combination treatment of patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression. Conclusion: Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.",
author = "Peter Schmid and Pinder, {Sarah E.} and Duncan Wheatley and Jane Macaskill and Charles Zammit and Jennifer Hu and Robert Price and Nigel Bundred and Sirwan Hadad and Alice Shia and Sarker, {Shah Jalal} and Louise Lim and Patrycja Gazinska and Natalie Woodman and Darren Korbie and Matt Trau and Paul Mainwaring and Steven Gendreau and Lackner, {Mark R.} and Mika Derynck and Wilson, {Timothy R.} and Hannah Butler and Gemma Earl and Peter Parker and Arnie Purushotham and Alastair Thompson",
year = "2016",
month = "6",
day = "10",
doi = "10.1200/JCO.2015.63.9179",
language = "English",
volume = "34",
pages = "1987--1994",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "17",

}

Schmid, P, Pinder, SE, Wheatley, D, Macaskill, J, Zammit, C, Hu, J, Price, R, Bundred, N, Hadad, S, Shia, A, Sarker, SJ, Lim, L, Gazinska, P, Woodman, N, Korbie, D, Trau, M, Mainwaring, P, Gendreau, S, Lackner, MR, Derynck, M, Wilson, TR, Butler, H, Earl, G, Parker, P, Purushotham, A & Thompson, A 2016, 'Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer', Journal of Clinical Oncology, vol. 34, no. 17, pp. 1987-1994. https://doi.org/10.1200/JCO.2015.63.9179

Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. / Schmid, Peter (Lead / Corresponding author); Pinder, Sarah E.; Wheatley, Duncan; Macaskill, Jane; Zammit, Charles; Hu, Jennifer; Price, Robert; Bundred, Nigel; Hadad, Sirwan; Shia, Alice; Sarker, Shah Jalal; Lim, Louise; Gazinska, Patrycja; Woodman, Natalie; Korbie, Darren; Trau, Matt; Mainwaring, Paul; Gendreau, Steven; Lackner, Mark R.; Derynck, Mika; Wilson, Timothy R.; Butler, Hannah; Earl, Gemma; Parker, Peter; Purushotham, Arnie; Thompson, Alastair.

In: Journal of Clinical Oncology, Vol. 34, No. 17, 10.06.2016, p. 1987-1994.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer

AU - Schmid, Peter

AU - Pinder, Sarah E.

AU - Wheatley, Duncan

AU - Macaskill, Jane

AU - Zammit, Charles

AU - Hu, Jennifer

AU - Price, Robert

AU - Bundred, Nigel

AU - Hadad, Sirwan

AU - Shia, Alice

AU - Sarker, Shah Jalal

AU - Lim, Louise

AU - Gazinska, Patrycja

AU - Woodman, Natalie

AU - Korbie, Darren

AU - Trau, Matt

AU - Mainwaring, Paul

AU - Gendreau, Steven

AU - Lackner, Mark R.

AU - Derynck, Mika

AU - Wilson, Timothy R.

AU - Butler, Hannah

AU - Earl, Gemma

AU - Parker, Peter

AU - Purushotham, Arnie

AU - Thompson, Alastair

PY - 2016/6/10

Y1 - 2016/6/10

N2 - Purpose: Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy. Patients and Methods: In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to 2 weeks of preoperative treatment with anastrozole 1 mg once per day (n = 26) or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49). The primary end point was inhibition of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment. Results: There was significantly greater geometric mean Ki-67 suppression of 83.8% (one-sided 95% CI, ≥ 79.0%) for the combination and 66.0% (95% CI, ≤ 75.4%) for anastrozole (geometric mean ratio [combination: anastrozole], 0.48; 95% CI, ≤ 0.72; P = .004). PIK3CA mutations were not predictive of response to pictilisib, but there was significant interaction between response to treatment and molecular subtype (P =.03);for patients with luminal B tumors, the combination:anastrozole geometric mean ratio of Ki-67 suppression was 0.37 (95% CI, ≤ 0.67; P = .008), whereas no significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98). Multivariable analysis confirmed Ki-67 response to the combination treatment of patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression. Conclusion: Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.

AB - Purpose: Preclinical data support a key role for the PI3K pathway in estrogen receptor-positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib (GDC-0941) can increase the antitumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy. Patients and Methods: In this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to 2 weeks of preoperative treatment with anastrozole 1 mg once per day (n = 26) or the combination of anastrozole 1 mg with pictilisib 260 mg once per day (n = 49). The primary end point was inhibition of tumor cell proliferation as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment. Results: There was significantly greater geometric mean Ki-67 suppression of 83.8% (one-sided 95% CI, ≥ 79.0%) for the combination and 66.0% (95% CI, ≤ 75.4%) for anastrozole (geometric mean ratio [combination: anastrozole], 0.48; 95% CI, ≤ 0.72; P = .004). PIK3CA mutations were not predictive of response to pictilisib, but there was significant interaction between response to treatment and molecular subtype (P =.03);for patients with luminal B tumors, the combination:anastrozole geometric mean ratio of Ki-67 suppression was 0.37 (95% CI, ≤ 0.67; P = .008), whereas no significant Ki-67 response was observed for pictilisib in luminal A tumors (1.01; P = .98). Multivariable analysis confirmed Ki-67 response to the combination treatment of patients with luminal B tumors irrespective of progesterone receptor status or baseline Ki-67 expression. Conclusion: Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer.

U2 - 10.1200/JCO.2015.63.9179

DO - 10.1200/JCO.2015.63.9179

M3 - Article

C2 - 26976426

AN - SCOPUS:84971659136

VL - 34

SP - 1987

EP - 1994

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -